It is indeed well-known that SRL treatment acts centrally not only by inhibiting GH release and consecutively decreasing IR but also by decreasing pancreatic insulin secretion and thus potentially impairing glycemic control [36, 37], although some studies failed to show any change in glucose and insulin metabolism during acromegaly treatment [38]. This evidence concerns the gene GH1 and acromegaly.